Predilife
Founded 2004
About Predilife
PrediLife develops innovative predictive medicine solutions that combine proven medical techniques (genetic testing, medical imaging etc.) with mathematical models using a large amount of statistical data, which potentially allow individuals to ascertain their own risk profile regarding the occurrence of a large number of serious diseases. The company markets its MammoRisk® personalised breast cancer screening solution in Europe and the United States. This combines medical imaging’from PrediLife’s proprietary DenSeeMammo software for measuring breast density’with Big Data and statistics through a scoring tool that uses patient-related data (age, breast density, family history, biopsy results, ethnic origin) and a study of the patient’s genetic profile through a genetic test, to establish a polygenic risk score. MammoRisk® addresses demand among women and medical practitioners for screening programmes that are personalised to reflect the risk of breast cancer.
Company Facts
- Founded: 2004
- Operating status: IPO
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Website: predilife.com
- Phone: 01 42 11 42 11
Social Profiles
Canonical: https://fsome.com/organization/predilife-8448826 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.